Prediction role of seven SNPs of DNA repair genes for survival of gastric cancer patients receiving chemotherapy.

We aimed to investigate DNA repair gene expression of response to chemotherapy among gastric patients, and roles in the prognosis of gastric cancer. A total of 209 gastric cancer patients were included in this study between January 2007 and December 2008, all treated with chemotherapy. Polymorphisms were detected by real time PCR with TaqMan probes, and genomic DNA was extracted from peripheral blood samples. The overall response rate was 61.2%. The median progression and overall survivals were 8.5 and 18.7 months, respectively. A significant increased treatment response was found among patients with XPG C/T+T/T or XRCC1 399G/ A+A/A genotypes, with the OR (95% CI) of 2.14 (1.15-4.01) and 1.75 (1.04-3.35) respectively. We found XPG C/T+T/T and XRCC1 399 G/A+A/A were associated with a longer survival among gastric cancer patients when compared with their wide type genotypes, with HRs and 95% CIs of 0.49 (0.27-0.89) and 0.56 (0.29-0.98) respectively. Selecting specific chemotherapy based on pretreatment genotyping may be an innovative strategy for further studies.

• Publication year

  2012

• Venue

  Asian Pacific Journal of Cancer Prevention

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.7314/APJCP.2012.13.12.6187PMID 23464428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck

  2012cited by this paper
• Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations

  2012cited by this paper
• [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].

  2011cited by this paper
• Role of ERCC5 polymorphism in risk of hepatocellular carcinoma.

  2011cited by this paper
• Single Nucleotide Polymorphisms in Nucleotide Excision Repair Genes XPA, XPD, XPG and ERCC1 in Advanced Colorectal Cancer Patients Treated with First-Line Oxaliplatin/Fluoropyrimidine

  2008influential reference
• Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

  2008cited by this paper
• Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis

  2007cited by this paper
• Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?

  2007cited by this paper
• Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized

  2007cited by this paper
• Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.

  2007cited by this paper
• Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

  2006cited by this paper
• Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

  2006cited by this paper
• Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway

  2006cited by this paper
• Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.

  2006cited by this paper
• Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.

  2006cited by this paper
• DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

  2006cited by this paper
• Palliative chemotherapy for advanced gastric cancer.

  2004cited by this paper
• Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

  2004cited by this paper
• XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

  2004cited by this paper
• Global cancer statistics in the year 2000.

  2001influential reference

• Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy

  2017cites this paper
• Roles of XRCC1/XPD/ERCC1 Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization

  2016cites this paper
• Polymorphisms of multiple genes involved in NER pathway predict prognosis of gastric cancer

  2016influential citation
• XRCC1 Gene Polymorphism, Clinicopathological Characteristics and Stomach Cancer Survival in Thailand.

  2015cites this paper
• Association between Polymorphisms in XRCC1 Gene and Treatment Outcomes of Patients with Advanced Gastric Cancer: A Systematic Review and Meta-Analysis

  2014cites this paper
• Association of XRCC1 gene polymorphisms with susceptibility to gastric cancer in Chinese Han population

  2014cites this paper
• Nucleotide excision repair related gene polymorphisms and genetic susceptibility, chemotherapeutic sensitivity and prognosis of gastric cancer.

  2014cites this paper